Tags

Type your tag names separated by a space and hit enter

Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography.
J Neurol Neurosurg Psychiatry. 2012 Sep; 83(9):923-6.JN

Abstract

BACKGROUND

Amyloid imaging provides in vivo detection of the fibrillar amyloid-β (Aβ) plaques of Alzheimer's disease (AD). The positron emission tomography (PET) ligand, Pittsburgh Compound-B (PiB-C11), is the most well studied amyloid imaging agent, but the short half-life of carbon-11 limits its clinical viability. Florbetapir-F18 recently demonstrated in vivo correlation with postmortem Aβ histopathology, but has not been directly compared with PiB-C11.

METHODS

Fourteen cognitively normal adults and 12 AD patients underwent PiB-C11 and florbetapir-F18 PET scans within a 28-day period.

RESULTS

Both ligands displayed highly significant group discrimination and correlation of regional uptake.

CONCLUSION

These data support the hypothesis that florbetapir-F18 provides comparable information with PiB-C11.

Authors+Show Affiliations

Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. david.wolk@uphs.upenn.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22791901

Citation

Wolk, David A., et al. "Amyloid Imaging in Alzheimer's Disease: Comparison of Florbetapir and Pittsburgh compound-B Positron Emission Tomography." Journal of Neurology, Neurosurgery, and Psychiatry, vol. 83, no. 9, 2012, pp. 923-6.
Wolk DA, Zhang Z, Boudhar S, et al. Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography. J Neurol Neurosurg Psychiatry. 2012;83(9):923-6.
Wolk, D. A., Zhang, Z., Boudhar, S., Clark, C. M., Pontecorvo, M. J., & Arnold, S. E. (2012). Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography. Journal of Neurology, Neurosurgery, and Psychiatry, 83(9), 923-6. https://doi.org/10.1136/jnnp-2012-302548
Wolk DA, et al. Amyloid Imaging in Alzheimer's Disease: Comparison of Florbetapir and Pittsburgh compound-B Positron Emission Tomography. J Neurol Neurosurg Psychiatry. 2012;83(9):923-6. PubMed PMID: 22791901.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography. AU - Wolk,David A, AU - Zhang,Zheng, AU - Boudhar,Sanaa, AU - Clark,Christopher M, AU - Pontecorvo,Michael J, AU - Arnold,Steven E, Y1 - 2012/07/11/ PY - 2012/7/14/entrez PY - 2012/7/14/pubmed PY - 2012/10/30/medline SP - 923 EP - 6 JF - Journal of neurology, neurosurgery, and psychiatry JO - J Neurol Neurosurg Psychiatry VL - 83 IS - 9 N2 - BACKGROUND: Amyloid imaging provides in vivo detection of the fibrillar amyloid-β (Aβ) plaques of Alzheimer's disease (AD). The positron emission tomography (PET) ligand, Pittsburgh Compound-B (PiB-C11), is the most well studied amyloid imaging agent, but the short half-life of carbon-11 limits its clinical viability. Florbetapir-F18 recently demonstrated in vivo correlation with postmortem Aβ histopathology, but has not been directly compared with PiB-C11. METHODS: Fourteen cognitively normal adults and 12 AD patients underwent PiB-C11 and florbetapir-F18 PET scans within a 28-day period. RESULTS: Both ligands displayed highly significant group discrimination and correlation of regional uptake. CONCLUSION: These data support the hypothesis that florbetapir-F18 provides comparable information with PiB-C11. SN - 1468-330X UR - https://www.unboundmedicine.com/medline/citation/22791901/Amyloid_imaging_in_Alzheimer's_disease:_comparison_of_florbetapir_and_Pittsburgh_compound_B_positron_emission_tomography_ L2 - https://jnnp.bmj.com/lookup/pmidlookup?view=long&pmid=22791901 DB - PRIME DP - Unbound Medicine ER -